drugset
drugset / Trial / NCT01069926

To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients

NCT01069926 ↗

Phase 1 Completed 21 enrolled AstraZeneca
NaSingle-groupOpen-label

Summary

To assess the pharmacokinetics of AZD1656, and its metabolite, in type 2 diabetes mellitus patients with varying degrees of renal impairment and to compare the results with those in patients with normal renal function.

Timeline

Start
2010-03
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1656 Small molecule — Oral

Indications

hypoglycemia